The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.

0949 ET – Novo Nordisk’s effort to usurp Pfizer’s bid for Metsera looks a very defensive move, Deutsche Bank analysts Emmanuel Papadakis and Henrietta Boeg write. The $9 billion bid was thoroughly unexpected and the bank questions what it implies for Novo Nordisk’s confidence in its own obesity programs. It also seems unlikely that the move is unrelated to recent board changes, Deutsche Bank adds. The bank has a buy rating and 600 Danish kroner target price for the stock. Shares fall 2.7% to 314 kroner. (dominic.chopping@wsj.com)

Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8